Research programme: beta-2 adrenoceptor agonists - GlaxoSmithKline/Innoviva

Drug Profile

Research programme: beta-2 adrenoceptor agonists - GlaxoSmithKline/Innoviva

Alternative Names: 293521; 324279; 849117; GSK 293521; GSK 324279; GSK 849117; Horizon programme; LABA programme - GlaxoSmithKline/Innoviva; RELOVAIR programme; THRX-666558

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Mar 2010 No development reported - Preclinical for Asthma in USA (Inhalation)
  • 19 Mar 2010 No development reported - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 19 Mar 2010 The generation of development candidates from this research programme appears to have ceased
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top